Entrada Therapeutics (TRDA) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 10, 2026, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and vote by June 9, 2026.

Voting matters and shareholder proposals

• Election of two directors: Peter S. Kim, Ph.D., and Bernhardt Zeiher, M.D.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Approval of Amendment No. 1 to the 2021 Stock Option and Incentive Plan.

• Approval of Amendment No. 1 to the 2021 Employee Stock Purchase Plan.

• Proxies may vote on other matters at the discretion of the Board during the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals and director nominees.